Cadila Healthcare gets US nod to market three drugs

New Delhi, Mar 19 (UNI) Cadila Healthcare Ltd today said it has received three product approvals from the US Food and Drug Administration to sell its medicines in the US.

The group has received the nod to market its immuno-suppresant drug Azathioprine Tablets 50 mg, and tentative approvals for Divalproex Sodium Extended Release Tablets 250 and 500 mg, an anti-convulsant, and Venlafaxine Hydrochloride Tablets 25, 37.5, 50, 75 and 100 mg, an anti-depressant.

The company will market the drugs through its US subsidiary Zydus Pharmaceuticals (USA) Inc, a statement said.

The branded sales in the US market of Azathioprine Tablets, is estimated at 113 million dollars in 2006, as per the National Drug Code (NDC).

The branded sales of Divalproex Sodium Extended Release was estimated at 700 million dollars in 2006 and that of Venlafaxine Hydrochloride Tablets was estimated at 141 million dollars in 2006 as per NDC.

The group now has 22 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 46 ANDAs and 46 DMFs.

UNI